WBWojciech Baran

Wojciech Baran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wojciech Baran has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Emergency contraception without prescription. Ethical, medical and legal analysis of EllaOne accessibility

    by Wojciech Baran, Patrycja Bartkiewicz

    Debata publiczna dotycząca tematu antykoncepcji postkoitalnej odżyła, gdy na początku 2024 roku Rada Ministrów przyjęła projekt nowelizacji, na mocy której produkt leczniczy EllaOne – octan uliprystalu miałby być ponownie dostępny bez recepty dla wszystkich osób, które ukończyły 15. rok życia. W 2017 roku, uzasadniając to względami bezpieczeństwa i obawą o zdrowie kobiet stosujących antykoncepcję awaryjną, ograniczono dostępność produktu EllaOne, zezwalając na jego wydanie wyłącznie z przepisu lekarza. Zwolennicy szerokiej dostępności antykoncepcji postkoitalnej zwracają uwagę na to, że EllaOne jest lekiem bezpiecznym, a efekty niepożądane są stosunkowo rzadkie i nie stanowią zagrożenia dla zdrowia. Ponadto konieczność uzyskania recepty wydłuża czas między stosunkiem a zażyciem leku, co może wpłynąć na obniżenie skuteczności oraz wiąże się z dodatkowymi kosztami. Przeciwnicy zaś powołują się na fakt, że biologiczny efekt octanu uliprystalu na endometrium może uniemożliwić implantację, utożsamiając lek ze środkiem wczesnoporonnym. Dyskurs dotyczący antykoncepcji awaryjnej wymaga przytoczenia zarówno argumentów biologicznych i medycznych, jak również refleksji nad definicją początku życia ludzkiego, nie jest wolny od wpływów ideologicznych, i nieodłącznie wiąże się z silnymi emocjami. Zmiany w regulacjach dotyczących dostępności leku EllaOne stanowią żywy dowód na to, że spór etyczny jest bezpośrednio odzwierciedlony w zmianach prawodawstwa.

  • Open Access

    Use of rituximab in the treatment of pemphigus vulgaris in a juvenile patient

    by Hanna Róża Cisoń, Wojciech Baran, Rafał Białynicki-Birula

    Introduction: Pemphigus vulgaris is a chronic autoimmune blistering disorder characterised by the production of autoantibodies against desmogleins, resulting in intraepithelial blister formation. Despite advancements in treatment options, some patients experience disease progression...

  • Open Access

    Linear IgA bullous dermatosis with Koebner phenomenon in a liver transplant patient

    by Bartosz Ptak, Emilia Knosala, Grażyna Wąsik, Rafał Białynicki-Birula, Wojciech Baran, Aleksandra Batycka-Baran

    Linear IgA bullous dermatosis (LABD) is a rare, acquired autoimmune disease which is characterized by itchy, clustered, subepidermal bullae with linear IgA deposits at the dermo-epidermal junction in direct immunofluorescence assay (DIF). In 1979, Chorzelski and Jab³oñska distinguished LABD as a...


  • Open Access

    Increased Serum Levels of S100A4 and S100A15 in Individuals Suffering from Hidradenitis Suppurativa

    by Aleksandra Batycka-Baran, Łukasz Matusiak, Danuta Nowicka-Suszko, Jacek C. Szepietowski, Wojciech Baran

    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Recently, some S100 proteins have been suggested to play an important role in the pathogenesis of chronic immune-mediated inflammatory diseases and they may constitute valuable biomarkers for these diseases’ diagnosis and monitoring. The objective of the current study was to investigate, for the first time, serum levels of S100A4 and S100A15 in individuals suffering from HS. Furthermore, we assessed the associations between S100A4 and S100A15 serum levels and the severity of disease, CRP serum concentration and some demographic and clinical data. Serum levels of S100A4 and S100A15 were evaluated with the commercially available ELISA kit according to the manufacturer’s instructions. The serum level of S100A4 in individuals with HS was significantly elevated as compared to controls, with the highest level found in the individuals in Hurley stage II. The S100A15 serum level was positively correlated with the CRP concentration and was associated with the severity of the disease. The serum level of S100A15 in the individuals in Hurley stage III was significantly elevated compared to that of the controls and the individuals with HS in Hurley stages I and II. S100A4 and S100A15 may be considered as new serum biomarkers for the monitoring of HS progression, and they may play a role in the pathogenesis of HS by promoting inflammatory process and fibrosis.


  • Open Access

    Side-effects Associated with Gel Nail Polish: A Self-questionnaire Study of 2,118 Respondents

    by J Putek, T Przybyla, J Szepietowski, W Baran, A Batycka-Baran

    Gel nail polish is commonly used in manicures; how­ever, research into the side-effects of gel nail...


  • Open Access

    Increased Serum Level and High Tissue Immunoexpression of Interleukin 17 in Cutaneous Lichen Planus: A Novel Therapeutic Target for Recalcitrant Cases?

    by Magdalena Żychowska, Aleksandra Batycka-Baran, Wojciech Baran

    Background. Interleukin-17 is supposed to play an important role in the pathogenesis of oral lichen planus (OLP). However, there is scarce data in the literature on its significance in the cutaneous variant of the disease. Objectives. To determine the serum level and tissue immunoexpression of IL-17 in cutaneous lichen planus (CLP). Methods. Fifty-two adult patients with CLP, without any significant autoimmune or inflammatory conditions, were included in the first part of the study. The control group consisted of 27 age- and sex-matched healthy volunteers. Serum concentration of IL-17 was quantified using enzyme-linked immunosorbent assay (ELISA) kit. In the second part of the study, the tissue expression of IL-17 was assessed in archival paraffin-embedded biopsy specimens from CLP (n=14) against normal control tissues (n=11) using immunohistochemical assays. The expression was evaluated using Zeiss Axio Imager A2 light microscope. Positively stained cells were counted in 10 fields of view for biopsy specimen at 200x magnification, and the mean value was calculated. Results. The serum level of IL-17 was significantly elevated in patients with CLP, compared with healthy volunteers (0.218±0.221 ng/ml versus 0.126±0.058 ng/ml, respectively; p=0.025). No correlation was found between the serum concentration of IL-17 and patient age, gender, disease duration, extent of skin involvement, the presence or intensity of pruritus, and coexistence of mucosal lesions. In tissue samples from CLP lesions, significantly higher numbers of cells expressing IL-17 were found when compared to a healthy skin (p<0.001). Conclusion. Elevated serum concentration of IL-17 and high expression in a lesional skin support the hypothesis that IL-17 is implicated in the immunopathogenesis of CLP. These findings may constitute a premise for the future use of anti-IL-17 monoclonal antibodies in the treatment of severe and recalcitrant forms of CLP.


  • Erythroderma

    by Wojciech Baran, Jacek Szepietowski

  • Multiple Blisters Over the Dorsum of the Hand

    by Wojciech Baran, Jacek Szepietowski

  • Open Access

    Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study

    by Laura K. Ferris, Elyssa Ott, Jingzhi Jiang, H. Chih-Ho Hong, Shu Li, Chenglong Han, Wojciech Baran

    Objectives: Guselkumab, an interleukin-23 antagonist, is approved for self-administration with the UltraSafe Plus™ syringe to treat moderate-to-severe plaque-type psoriasis. We evaluated the efficacy, safety, pharmacokinetics, and acceptability of guselkumab administered using a novel patient-controlled injector (One-Press) in psoriasis patients. Materials and methods: This Phase 3, multicentre, double-blind, placebo-controlled study (ORION, Clinicaltrials.gov identifier-NCT02905331) randomized adults with moderate-to-severe psoriasis (4:1) to guselkumab 100 mg at Weeks 0/4/12/20/28 or placebo at Weeks 0/4/12 with crossover to guselkumab 100 mg at Weeks 16/20/28. Week 16 co-primary endpoints were the proportions of patients achieving Investigator Global Assessment (IGA) cleared/minimal (IGA 0/1) and Psoriasis Area and Severity Index 90% improvement (PASI90) responses. One-Press usability/acceptability was evaluated using the Self-Injection Assessment Questionnaire (SIAQ) and Patient-Controlled Injection Device Questionnaire. Final assessments occurred at Week 40. Results: At Week 16, significantly higher proportions of guselkumab-treated (N = 62) than placebo-treated (N = 16) patients achieved IGA 0/1 (80.6% vs. 0.0%, p < .001) and PASI90 (75.8% vs. 0.0%, p < .001) responses. Adverse events were comparable between treatments. SIAQ results demonstrated 99% (68/69) of patients were satisfied/very satisfied with One-Press at Week 28. Conclusions: Guselkumab administered using the One-Press patient-controlled injector was efficacious and well-tolerated in moderate-to-severe psoriasis patients, consistent with previously reported Phase-3 studies of guselkumab administered using UltraSafe Plus. One-Press was highly acceptable to patients.


  • Open Access

    Skin Autofluorescence, as a Measure of AGE Accumulation in Individuals Suffering from Chronic Plaque Psoriasis

    by Karolina Kopeć-Pyciarz, Irena Makulska, Danuta Zwolińska, Łukasz Łaczmański, Wojciech Baran

    Background. Psoriasis is currently regarded as a chronic systemic inflammatory disease associated with increased cardiovascular risk. Advanced glycation end products (AGEs) contribute to the development of atherosclerosis. Objectives. The aim of the study was the assessment of skin autofluorescence (SAF), as a measure of AGE accumulation, in individuals suffering from chronic plaque psoriasis without any comorbid conditions. Methods. A study group consisted of 70 patients with chronic plaque psoriasis without any comorbid conditions and 59 healthy controls, matched by age and gender. AGE accumulation was assessed by SAF (AGE Reader, DiagnOptics BV) which is a validated and noninvasive technique. Relations between SAF and some clinical and laboratory data were assessed. Results. SAF was positively correlated with age both in patients with psoriasis and controls (R=0.722, p<0.00001 and R=0.613, p<0.00001, respectively). There was significantly increased SAF in patients with psoriasis with elevated levels of C-reactive protein (CRP) and increased erythrocyte sedimentation rate (ESR) compared to controls (p<0.00001; p<0.00001, respectively, after adjustment to age). Increased SAF was found in psoriatic patients with prediabetes (HbA1c 5.7–6.4%) compared to controls (p<0.0012, after adjustment to age). Conclusion. Systemic inflammation (increased CRP level), prediabetes, and aging may influence enhanced AGE accumulation in patients with psoriasis without any comorbidities. SAF may be considered as a useful, noninvasive method to identify patients with psoriasis at increased cardiovascular risk.